Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 1
1994 3
1995 5
1996 7
1997 9
1998 19
1999 48
2000 34
2001 38
2002 44
2003 34
2004 40
2005 36
2006 38
2007 26
2008 34
2009 35
2010 33
2011 48
2012 52
2013 47
2014 46
2015 38
2016 45
2017 47
2018 44
2019 52
2020 42
2021 39
2022 31
2023 33
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

954 results

Results by year

Filters applied: . Clear all
Page 1
Repaglinide.
[No authors listed] [No authors listed] 2019 Feb 7. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2019 Feb 7. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000151 Free Books & Documents. Review.
No information is available on the use of repaglinide during breastfeeding. Repaglinide is a weak acid that is over 98% protein bound, so it is unlikely to pass into breastmilk in clinically important amounts. ...If there is concern, monitoring of the breastfed infa …
No information is available on the use of repaglinide during breastfeeding. Repaglinide is a weak acid that is over 98% protei …
Repaglinide.
[No authors listed] [No authors listed] 2019 May 21. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2019 May 21. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644186 Free Books & Documents. Review.
Repaglinide is a benzoic acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes. Repaglinide has been linked to rare instances of clinically apparent acute liver injury....
Repaglinide is a benzoic acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 dia …
Repaglinide.
Milner Z, Akhondi H. Milner Z, et al. 2023 Jul 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Jul 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 32644731 Free Books & Documents.
Repaglinide is a medication used in the management and treatment of diabetes mellitus Type 2. ...This activity outlines the indications, mechanism of action, and contraindications for repaglinide as a valuable agent in the management of diabetes mellitus type 2....
Repaglinide is a medication used in the management and treatment of diabetes mellitus Type 2. ...This activity outlines the indicatio …
Repaglinide.
Balfour JA, Faulds D. Balfour JA, et al. Drugs Aging. 1998 Aug;13(2):173-80. doi: 10.2165/00002512-199813020-00008. Drugs Aging. 1998. PMID: 9739505 Review.
Repaglinide is rapidly absorbed and eliminated, which may allow a relatively fast onset and offset of action. ...Addition of repaglinide to existing metformin therapy resulted in improved glycaemic control. ...
Repaglinide is rapidly absorbed and eliminated, which may allow a relatively fast onset and offset of action. ...Addition of repag …
Repaglinide-Induced Acute Pancreatitis.
Udongwo N, Mararenko A, Alchalabi H, Amin T, Lesniak C, Sharif Khawaja U. Udongwo N, et al. Cureus. 2021 Aug 7;13(8):e16983. doi: 10.7759/cureus.16983. eCollection 2021 Aug. Cureus. 2021. PMID: 34540388 Free PMC article.
Our team describes the case of an 84-year-old male that was found to have acute pancreatitis secondary to repaglinide, a commonly used medication for the management of diabetes mellitus. ...The patient was also found to have a blood-alcohol level at baseline and triglyceri …
Our team describes the case of an 84-year-old male that was found to have acute pancreatitis secondary to repaglinide, a commonly use …
Repaglinide: a review of its use in type 2 diabetes mellitus.
Scott LJ. Scott LJ. Drugs. 2012 Jan 22;72(2):249-72. doi: 10.2165/11207600-000000000-00000. Drugs. 2012. PMID: 22268393 Review.
Meglitinides, including repaglinide, have a distinct binding site at the beta-cell membrane, which differs from that of sulfonylureas, and corresponds to greater insulinotropic effects with repaglinide than with glibenclamide and/or glimepiride and a more rapid onse …
Meglitinides, including repaglinide, have a distinct binding site at the beta-cell membrane, which differs from that of sulfonylureas …
Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.
Culy CR, Jarvis B. Culy CR, et al. Drugs. 2001;61(11):1625-60. doi: 10.2165/00003495-200161110-00008. Drugs. 2001. PMID: 11577798 Review.
Patients can vary their meal timetable with repaglinide: the glucose-lowering efficacy of repaglinide was similar for patients consuming 2, 3 or 4 meals a day. ...Unlike glibenclamide, the risk of hypoglycaemia in patients receiving repaglinide was not increa …
Patients can vary their meal timetable with repaglinide: the glucose-lowering efficacy of repaglinide was similar for patients …
Repaglinide: prandial glucose regulation in clinical practice.
Owens DR, McDougall A. Owens DR, et al. Diabetes Obes Metab. 2000 Mar;2 Suppl 1:S43-8. doi: 10.1046/j.1463-1326.2000.0022s.x. Diabetes Obes Metab. 2000. PMID: 11225759 Review.
Repaglinide has few contraindications or drug interactions and can be used in a wide range of patients. ...When glucose targets are not met using repaglinide monotherapy, the combination of repaglinide with metformin can further improve glycaemic control by e …
Repaglinide has few contraindications or drug interactions and can be used in a wide range of patients. ...When glucose targets are n …
Repaglinide, a new oral antidiabetic agent: a review of recent preclinical studies.
Malaisse WJ. Malaisse WJ. Eur J Clin Invest. 1999 Jun;29 Suppl 2:21-9. doi: 10.1046/j.1365-2362.1999.00001.x. Eur J Clin Invest. 1999. PMID: 10383607 Review.
Repaglinide is a new carbamoylmethyl benzoic acid derivative that is structurally related to meglitinide. ...In vivo administration of an ester of succinic acid potentiates the insulin secretory response to concomitantly administered repaglinide. Repaglinide …
Repaglinide is a new carbamoylmethyl benzoic acid derivative that is structurally related to meglitinide. ...In vivo administration o …
Repaglinide as monotherapy in Type 2 diabetes.
Gomis R. Gomis R. Exp Clin Endocrinol Diabetes. 1999;107 Suppl 4:S133-5. doi: 10.1055/s-0029-1212168. Exp Clin Endocrinol Diabetes. 1999. PMID: 10522838 Review.
Repaglinide stimulates insulin release from beta-cells only in the presence of glucose. ...Hypoglycaemic events were reported in 16% of repaglinide-treated patients and 15-20% of sulphonylurea-treated patients. ...
Repaglinide stimulates insulin release from beta-cells only in the presence of glucose. ...Hypoglycaemic events were reported in 16% …
954 results